This study is testing a new treatment for Hodgkin lymphoma that has either come back (relapsed) or didn't respond to previous treatments (refractory). It combines a special antibody called yttrium-90 labeled anti-CD25 with a chemotherapy regimen known as BEAM (carmustine, etoposide, cytarabine, and melphalan). The yttrium-90 labeled anti-CD25 is an antibody (a protein made by your immune system) that has a radioactive substance attached. It's designed to kill cancer cells and shrink tumors. The BEAM chemotherapy drugs work in different ways to stop cancer cells from growing or spreading. We want to see how well this combined treatment prevents the cancer from returning for up to 5 years after treatment. You may be eligible if you are 18 or older with Hodgkin lymphoma that has relapsed or is refractory.

Study design

This is a phase II interventional study aiming to enroll 33 participants. It is testing a specific combination of treatments.

What's involved

You will receive 'cold' basiliximab and yttrium Y 90 basiliximab intravenously (IV) on day -14. You will also receive carmustine, etoposide, cytarabine, and melphalan IV over several days leading up to a stem cell infusion.

Compensation

Not stated in the trial record.

Follow-up

Your progression-free survival will be measured for up to 5 years after the transplant. Overall survival and other outcomes will be tracked for 100 days, 1 year, and 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.